Table I.
Clinical and pathological features of the patients (n=83).
| Characteristic | n (%) |
|---|---|
| Age, years | |
| ≤45 | 49 (59.0) |
| >45 | 34 (41.0) |
| Pre-NAC stage (based on ultrasound) | |
| T2 | 41 (49.4) |
| T3 | 24 (28.9) |
| T4 | 18 (21.7) |
| Post-NAC stage (based on resection pathology) | |
| T0 | 6 (7.2) |
| T1 | 23 (27.7) |
| T2 | 33 (39.8) |
| T3 | 12 (14.5) |
| T4 | 9 (10.8) |
| Tumor size changea | |
| Increase | 8 (9.6) |
| Decrease | 69 (83.1) |
| pCR | 6 (7.2) |
| NAC regimen | |
| TP | 32 (38.6) |
| TC | 15 (18.1) |
| CEF | 36 (43.4) |
| Positive axillary metastasis | 61 (73.5) |
| Estrogen receptor-positive | 37 (44.6) |
| Her2-positive | 51 (61.4) |
| Surgery | |
| Breast conserving | 2 (2.4) |
| Mastectomy | 81 (97.6) |
| Follow-up, monthsb | 45 (32–78) |
| Recurrence | 28 (33.7) |
| Mortality | 23 (27.7) |
a
Change between the initial size at ultrasound and final size at resection pathology;
b
Median (range).
NAC, neoadjuvant chemotherapy; pCR, pathological complete response; TP, docetaxel + platinum; TC, platinum + cyclophosphamide; CEF, 5-fluorouracil + epirubicin + cyclophosphamide.